Boao Lecheng expands its biomedical technology programmes

A regional pathway for new biomedical technologies

The July 2026 article reports that Boao Lecheng International Medical Tourism Pilot Zone in Hainan had 58 approved biomedical technology projects, including a group of 28 additional projects. It describes three broad areas: regenerative-cell approaches, immune-cell therapies and gene therapy.

The article is an overview of programmes in the pilot zone. Its project list should not be read as a national drug-approval list or as confirmation that every named treatment is available to every patient.

Three areas of development

Regenerative-cell projects described in the source address areas such as joint degeneration, respiratory disease, liver disease, reproductive conditions and autoimmune disorders. They involve different cell sources, including umbilical-cord, adipose, dental-pulp and menstrual-blood-derived cells.

Immune-cell programmes include dendritic-cell vaccines, natural killer cells, tumour-infiltrating lymphocytes, CAR-modified cells and oncolytic-virus approaches. The source also discusses allogeneic products intended to reduce preparation time. These technologies have different mechanisms, evidence and eligibility requirements.

Gene-therapy projects described in the article include inherited retinal disorders and thalassaemia, alongside exploratory approaches for neurological disease. Gene addition, gene editing and cell-based gene modification are distinct methods and should not be treated as interchangeable.

Understanding the reported costs

The article groups reported project prices into RMB 16,000–80,000, RMB 100,000–200,000 and RMB 200,000–480,000 bands. These are the article’s indicative figures, not a Chirona quotation or a verified all-inclusive hospital tariff. The required product, procedures, tests, hospital care and follow-up vary by programme.

The original article states that its information was current to July 2026 and included project approvals and price filings. Patients considering a specific programme need the treating institution to confirm its actual regulatory pathway, current availability, eligibility and written costs.

The projects listed in the article

The following list translates the 58 project descriptions included in the article. Inclusion records what that article lists; it does not independently establish a project’s approval status or clinical effectiveness.

1. Umbilical-cord mesenchymal stromal-cell injection for knee osteoarthritis
2. Airway basal stem-cell therapy for chronic obstructive pulmonary disease
3. Umbilical-cord-derived mesenchymal cells for heart failure with reduced ejection fraction
4. Airway basal stem cells for bronchiectasis
5. Airway basal stem cells for interstitial lung disease
6. Mesenchymal cells for complications following bone-marrow transplantation
7. Personalised dendritic-cell vaccines for malignancies
8. Gene therapy for inherited retinal dystrophy associated with biallelic RPE65 mutations
9. Cell-based vaccination targeting Epstein–Barr virus infection
10. Menstrual-blood-derived mesenchymal cells for pulmonary fibrosis
11. Umbilical-cord mesenchymal cells for premature ovarian insufficiency
12. Activated T lymphocytes for prevention of postoperative liver-cancer recurrence
13. Dental-pulp mesenchymal cells for periodontal disease
14. Umbilical-cord-derived mesenchymal cells (VUM02) for cirrhosis
15. Umbilical-cord mesenchymal cells for rheumatoid arthritis
16. Menstrual-blood-derived mesenchymal cells for decompensated cirrhosis
17. Autologous natural killer cells alongside immunotherapy for solid tumours
18. Umbilical-cord mesenchymal cells for knee osteoarthritis
19. Umbilical-cord mesenchymal cells for type 2 diabetes
20. Autologous dendritic cells for immune-related solid tumours, including pancreatic and colorectal cancer
21. Non-gene-modified dendritic-cell vaccines for EBV-associated haematological malignancies
22. Autologous natural killer cells as adjunctive solid-tumour therapy and recurrence prevention
23. M-021001 cell therapy for meniscal injury
24. Gene-edited autologous haematopoietic stem cells for transfusion-dependent beta-thalassaemia
25. AAV gene therapy for haemophilia A
26. Allogeneic endothelial progenitor cells for severe lower-limb ischaemia
27. Allogeneic hepatocytes for cirrhosis
28. Adipose-derived stem cells expressing GLP-1 and FGF21 for type 2 diabetes
29. Human iPSC-derived motor-neuron progenitors for amyotrophic lateral sclerosis
30. B7-H3-targeted allogeneic universal CAR-gamma-delta T cells (QH104A)
31. Recombinant human L-21 oncolytic vaccinia virus for soft-tissue sarcoma
32. ZVS101e gene therapy for Bietti crystalline dystrophy
33. EXG102-031 gene therapy for wet age-related macular degeneration
34. FT-003 gene therapy for neovascular age-related macular degeneration
35. Human embryonic-stem-cell-derived mesenchymal-like cells for intrauterine adhesions
36. Human amniotic epithelial cells for premature ovarian failure
37. Gene-modified autologous haematopoietic stem cells (KL003) for transfusion-dependent thalassaemia
38. Dental-follicle mesenchymal cells for periodontal disease
39. Adipose mesenchymal cells with minimally invasive surgery for complex anal fistula
40. Umbilical-cord mesenchymal cells for systemic lupus erythematosus
41. Amniotic mesenchymal cells for diminished ovarian reserve
42. Tumour-infiltrating lymphocytes for solid tumours
43. Autologous RAK cells after curative surgery for hepatocellular carcinoma
44. Personalised tumour-neoantigen peptides following curative pancreatic-cancer surgery
45. Gene-modification therapy for amyotrophic lateral sclerosis
46. Autologous unmodified tumour-infiltrating lymphocytes for lung cancer and melanoma
47. Mesothelin-targeted CAR-T cells secreting anti-PD-1 antibodies for malignant mesothelioma
48. Oncolytic viruses for advanced solid tumours
49. Gene therapy for inherited retinal disease associated with RDH12 variants
50. Autologous 5cTIL tumour immune-cell therapy
51. Autologous CD7-targeted CAR-T cells (PA3-17) for adults with relapsed or refractory CD7-positive haematolymphoid malignancies
52. Cell therapy for B-cell non-Hodgkin lymphoma
53. Autologous haematopoietic-stem-cell gene therapy for transfusion-dependent thalassaemia
54. Umbilical-cord mesenchymal cells for ankylosing spondylitis
55. CAStem cell therapy for pulmonary fibrosis
56. Mesenchymal stromal/stem cells for interstitial lung disease
57. Allogeneic bone-marrow mesenchymal cells for acute-on-chronic liver failure
58. Central-memory lymphocytes for hepatocellular carcinoma